Opinion|Videos|March 25, 2025
Navigating Cost Considerations in Treatment Selection of mCRC Agents
Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key payer-related challenges (eg, step edits, prior authorizations) that impact access to third-line therapies for patients with mCRC?
- How do payer requirements influence treatment sequencing and decision-making in the third-line setting?
- How do the costs associated with adverse events across the different third-line treatments (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab) influence treatment selection?
Advertisement
Related to this article
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Keynote Address Tackles AI’s Role in Health Care, Eye Care
5